Primary PFS and safety analyses of a randomized Phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

IMA950 multipeptide vaccine adjuvanted with poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients

Phase 1 study of E7046, a PGE2 receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment (TME)

IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Efficacy of PEGylated human IL-10 (AM0010) in combination with anti-PD-1 blockade in patients (pts) with metastatic renal cell carcinoma (mRCC): A phase 1b trial

INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12) immunotherapy in biochemically relapsed prostate cancer

Deciphering the intra-tumoural T cell receptor repertoire in patients with NSCLC within the lung TRACERx study

A Phase 1b/2 Study of Omaveloxolone in Combination with Checkpoint Inhibitors in Patients with Unresectable or Metastatic Melanoma

T cell responses in patients with melanoma resistant to multiple immunotherapies

T-cell therapy in combination with vemurafenib in BRAF mutated metastatic melanoma patients

Health Status of Patients (Pts) with Gastric Cancer (GC) Receiving Nivolumab Monotherapy In CheckMate-032 (CM-032) and Predicted Scores for ATTRACTION-2

A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy

KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)

Peptide vaccination against PD-L1 in multiple myeloma: A phase I trial